StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) stock

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.55−0.01 (-1.41%)

Close on Nov 13, 2026Market cap $47.63MP/E –Yield 0.00%

Rein Therapeutics, Inc. reported revenue of $0 for the twelve months to Sep 30, 2026. At the latest close the market valued the company at $47.63M.

Revenue
$0
TTM Q3 2026
Operating income
-$50.96M
TTM Q3 2026
EPS, diluted
-$1.44
TTM Q3 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026

Valuation

Market cap
$47.63M
P/E ratio
–
Price to sales
–
Price to book
0.86
Dividend yield
0.00%
Free cash flow yield
–

Fundamentals

Revenue
$0
Net income
-$49.72M
EPS, diluted
-$1.44
Book value per share
$0.60
Diluted shares
88M

Trading

Previous close
$0.56
Open
$0.55
Day's range
$0.50 – $0.57
Volume
488,672
Average volume (20 days)
349,337
Beta (5 years)
1.42
52-week range
$0.50 – $2.10
RSI (14 days)
37.3
Volatility (1 year)
85.3%
Relative volume
1.16×
WACC
12.2%

Market cap history

Month-end market cap since 2017, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodRNTXS&P 500DifferenceRNTX per yearS&P 500 per year
1 month-26.8%-3.0%−23.8 pts
3 months-29.9%-2.8%−27.1 pts
Year to date-52.4%+11.5%−63.9 pts
1 year-59.1%+13.5%−72.6 pts
3 years-67.3%+77.7%−145.0 pts-31.1%+21.1%
5 years-96.8%+72.6%−169.4 pts-49.8%+11.5%

Twelve years at a glance

Fiscal years 2014 to 2025 and trailing twelve months, USD

Revenue

$0

Operating income

-$50.96M

Net income

-$49.72M

EPS, diluted

-$1.44

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Rein Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Rein Therapeutics

Pharmaceutical Preparations

The company is a clinical-stage biopharmaceutical business that develops novel therapeutics targeting orphan pulmonary and fibrosis indications with limited or no approved therapies. Its primary pipeline candidate is LTI-03, an inhaled peptide therapeutic derived from the Cav1 protein designed to protect lung epithelial cells and inhibit pro-fibrotic pathways in idiopathic pulmonary fibrosis. The company also developed LTI-01, a proenzyme for treating loculated pleural effusion, alongside preclinical programs for cystic fibrosis and systemic fibrosis, although active development on these secondary programs is paused. Because its drug candidates remain in clinical and preclinical development, the company has no commercialized products, generates no product sales revenue, and currently lacks commercial customers or internal sales, marketing, and distribution infrastructure.

Company profile, executives and history

Rein Therapeutics stock: common questions

What is Rein Therapeutics's stock price?

RNTX closed at $0.55 on Nov 13, 2026, down 1.41% on the day. Over the past 52 weeks it traded between $0.50 and $2.10.

What is Rein Therapeutics's market cap?

Rein Therapeutics was worth $47.63M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

What is RNTX's P/E ratio?

Rein Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.44), so it has no meaningful P/E ratio.

How much revenue does Rein Therapeutics make?

Rein Therapeutics reported revenue of $0 for the twelve months to Sep 30, 2026.

Does Rein Therapeutics pay a dividend?

No. Rein Therapeutics has not paid a cash dividend over the last twelve months.

How has RNTX stock performed over the past year?

Including dividends, RNTX returned -59.1% over the past year, against +13.5% for the S&P 500.

How many RNTX shares are sold short?

1M shares were sold short at the latest FINRA report, 0.91% of the float, or 2.1 days of average trading volume.

Who are Rein Therapeutics's competitors?

Companies most similar to Rein Therapeutics by business, industry and size include GRI, TVRD, CMMB, GHRS, MLYS.

See a number that looks wrong?